These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 30149235

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results.
    De Rose F, Fogliata A, Franceschini D, Navarria P, Villa E, Iftode C, D'Agostino G, Cozzi L, Lobefalo F, Mancosu P, Tomatis S, Scorsetti M.
    Radiat Oncol; 2016 Sep 17; 11(1):120. PubMed ID: 27639373
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Accelerated hypofractionated adjuvant whole breast radiation with simultaneous integrated boost using volumetric modulated arc therapy for early breast cancer: A phase I/II dosimetric and clinical feasibility study from a tertiary cancer care centre of India.
    Mondal D, Julka PK, Sharma DN, Jana M, Laviraj MA, Deo SV, Roy S, Guleria R, Rath GK.
    J Egypt Natl Canc Inst; 2017 Mar 17; 29(1):39-45. PubMed ID: 28343538
    [Abstract] [Full Text] [Related]

  • 5. Hypofractionated volumetric modulated arc therapy in ductal carcinoma in situ: toxicity and cosmetic outcome from a prospective series.
    De Rose F, Fogliata A, Franceschini D, Iftode C, Torrisi R, Masci G, Sagona A, Tinterri C, Testori A, Gatzemeier W, Fernandes B, Rahal D, Cozzi L, Santoro A, Scorsetti M.
    Br J Radiol; 2018 May 17; 91(1085):20170634. PubMed ID: 29322827
    [Abstract] [Full Text] [Related]

  • 6. Long term results of a phase II trial of hypofractionated adjuvant radiotherapy for early-stage breast cancer with volumetric modulated arc therapy and simultaneous integrated boost.
    Franceschini D, Fogliata A, Spoto R, Dominici L, Lo Faro L, Franzese C, Comito T, Lobefalo F, Reggiori G, Cozzi L, Sagona A, Gentile D, Scorsetti M.
    Radiother Oncol; 2021 Nov 17; 164():50-56. PubMed ID: 34537289
    [Abstract] [Full Text] [Related]

  • 7. Hypofractionated Simultaneous Integrated Boost Radiotherapy Versus Conventional Fractionation Radiotherapy of Early Breast Cancer After Breast-Conserving Surgery: Clinical Observation and Analysis.
    Dong J, Yang Y, Han D, Zhao Q, Liu C, Sun H, Wang Z, Lin H, Huang W.
    Technol Cancer Res Treat; 2021 Nov 17; 20():15330338211064719. PubMed ID: 34898315
    [Abstract] [Full Text] [Related]

  • 8. Hypofractionated Whole Breast Irradiation and Simultaneous Integrated Boost in Large-breasted Patients: Long-term Toxicity and Cosmesis.
    De Rose F, Fogliata A, Franceschini D, Iftode C, D'Agostino GR, Comito T, Franzese C, Di Brina L, Clerici E, Loi M, Navarria P, Gatzemeier W, Testori A, Tinterri C, Lobefalo F, Tomatis S, Cozzi L, Scorsetti M.
    Clin Breast Cancer; 2020 Dec 17; 20(6):527-533. PubMed ID: 32665192
    [Abstract] [Full Text] [Related]

  • 9. Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial.
    Krug D, Baumann R, Krockenberger K, Vonthein R, Schreiber A, Boicev A, Würschmidt F, Weinstrauch E, Eilf K, Andreas P, Höller U, Dinges S, Piefel K, Zimmer J, Dellas K, Dunst J.
    Strahlenther Onkol; 2021 Jan 17; 197(1):48-55. PubMed ID: 33001241
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Acute and intermediate toxicity of 3-week radiotherapy with simultaneous integrated boost using TomoDirect: prospective series of 287 early breast cancer patients.
    Dicuonzo S, Leonardi MC, Raimondi S, Corrao G, Bagnardi V, Gerardi MA, Morra A, Zerella MA, Zaffaroni M, Pansini F, Cattani F, Luraschi R, Fodor C, Veronesi P, Orecchia R, Rojas DP, Jereczek-Fossa BA.
    Clin Transl Oncol; 2021 Jul 17; 23(7):1415-1428. PubMed ID: 33537865
    [Abstract] [Full Text] [Related]

  • 12. Hypofractionated Breast Radiation: Shorter Scheme, Lower Toxicity.
    Linares I, Tovar MI, Zurita M, Guerrero R, Expósito M, Del Moral R.
    Clin Breast Cancer; 2016 Aug 17; 16(4):262-8. PubMed ID: 26454613
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant breast inversely planned intensity-modulated radiotherapy with simultaneous integrated boost for early stage breast cancer : Results from a phase II trial.
    Meng J, Huang W, Mei X, Yu X, Pan Z, Ma J, Ma X, Chen J, Guo X, Yang Z.
    Strahlenther Onkol; 2020 Sep 17; 196(9):764-770. PubMed ID: 32318767
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy.
    De Santis MC, Bonfantini F, Di Salvo F, Dispinzieri M, Mantero E, Soncini F, Baili P, Sant M, Bianchi G, Maggi C, Di Cosimo S, Agresti R, Pignoli E, Valdagni R, Lozza L.
    Breast; 2016 Oct 17; 29():90-5. PubMed ID: 27476083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.